Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$11.09 USD
+0.05 (0.41%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $11.09 +0.01 (0.05%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.09 USD
+0.05 (0.41%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $11.09 +0.01 (0.05%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Zacks News
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -111.76% and 0.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 0% and 8.43%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -4% and 19.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 5.73% and 18.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Liquidia (LQDA) Up on Deal With Pharmosa to Co-Develop PH Drug
by Zacks Equity Research
Liquidia (LQDA) signs an exclusive licensing agreement with Pharmosa to jointly develop and commercialize PAH and PH-ILD treatment candidate, L606, in North America. Shares of the company rise 11%.
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 0% and 8.79%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength?
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 47.06% and 46.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Aravive (ARAV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aravive (ARAV) delivered earnings and revenue surprises of -39.39% and 298.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals (ANIP) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 11.76% and 8.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -18.85% and 73.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 7.04% and 6%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Vericel Corporation (VCEL) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 500% and 0.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Liquidia Technologies, Inc. (LQDA): Can Its 9.7% Jump Turn into More Strength?
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Are Medical Stocks Lagging Assertio (ASRT) This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Assertio (ASRT) This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.
Wall Street Analysts Think Liquidia Technologies, Inc. (LQDA) Could Surge 153%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 153.2% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Liquidia Technologies (LQDA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 22.22% and 9.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Acadia Healthcare (ACHC) This Year?
by Zacks Equity Research
Here is how Acadia Healthcare (ACHC) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.
Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 136%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Liquidia Technologies, Inc. (LQDA) points to a 136.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Liquidia Technologies (LQDA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Liquidia Technologies, Inc. (LQDA) and PolyPid Ltd. (PYPD) have performed compared to their sector so far this year.
Find Highly-Ranked Cheap Stocks Under $10 to Buy with this Screen
by Benjamin Rains
We used one of our Zacks screens to help show investors how to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying as we start to close out August.
Here's Why Liquidia Technologies, Inc. (LQDA) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Liquidia Technologies, Inc. (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.